Circulating 25-hydroxyvitamin D3 and survival after diagnosis with kidney cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 8, 2015, Pages 1277-1281

  Muller, David C ^a   Scelo, Ghislaine ^a   Zaridze, David ^b   Janout, Vladimir ^c   Holcatova, Ivana ^d   Navratilova, Marie ^e   Mates, Dana ^f   Midttun, Øivind ^g   Ueland, Per Magne ^h,i   Brennan, Paul ^a   Johansson, Mattias ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^f NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^g BEVITAL AS   (Norway)

^h UNIVERSITY OF BERGEN   (Norway)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIFEDIOL; VITAMIN D;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONCENTRATION PROCESS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; KIDNEY CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEASONAL VARIATION; VENOUS BLOOD; AGED; CASE CONTROL STUDY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VITAMIN D;

EID: 84941775696     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-1351     Document Type: Article

References (20)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
2. Cancer Research UK. Statistics and outlook for kidney cancer [Website]; 2014. [cited 2014 May 28]. Available from: http://www.cancerresearchuk. org/cancer-help/type/kidney-cancer/treatment/statistics-and-outlook-forkidney-cancer#stage.
3. Muller DC, Fanidi A, Midttun A, Steffen A, Dossus L, Boutron-Ruault MC, et al. Circulating 25-hydroxyvitamin D3 in relation to renal cell carcinoma incidence and survival in the EPIC cohort. Am J Epidemiol 2014;180: 810-20.
4. Gallicchio L, Moore LE, Stevens VL, Ahn J, Albanes D, Hartmuller V, et al. Circulating 25-hydroxyvitamin D and risk of kidney cancer cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 2010;172:47-57.
5. Joh HK, Giovannucci EL, Bertrand KA, Lim S, Cho E. Predicted plasma 25-hydroxyvitamin D and risk of renal cell cancer. J Natl Cancer Inst 2013;105:726-32.
6. Midttun A, Ueland PM. Determination of vitamins A, D and E in a small volume of human plasma by a high-throughput method based on liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2011;25:1942-8.
7. Lunn M, McNeil D. Applying cox regression to competing risks. Biometrics 1995;51:524.
8. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1-11.
9. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994;50:1064-72.
10. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-72.
11. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
12. Schöttker B, Haug U, Schomburg L, Köhrle J, Perna L,Müller H, et al. Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr 2013;97:782-93.
13. Virtanen JK, Nurmi T, Voutilainen S, Mursu J, Tuomainen TP. Association of serum 25-hydroxyvitamin D with the risk of death in a general older population in Finland. Eur J Nutr 2011;50: 305-12.
14. Hutchinson MS, Grimnes G, Joakimsen RM, Figenschau Y, Jorde R. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: the Troms-study. Eur J Endocrinol 2010;162:935-42.
15. Szulc P, Claustrat B, Delmas PD. Serum concentrations of 17b-E2 and 25-hydroxycholecalciferol (25OHD) in relation to all-cause mortality in older men-the MINOS study. Clin Endocrinol 2009; 71:594-602.
16. Semba RD, Houston DK, Ferrucci L, Cappola AR, Sun K, Guralnik JM, et al. Low serum 25-hydroxyvitamin D concentrations are associated with greater all-cause mortality in older community-dwelling women. Nutr Res 2009;29:525-30.
17. Pilz S, Dobnig H, Nijpels G, Heine RJ, Stehouwer CDA, Snijder MB, et al. Vitamin D and mortality in older men and women. Clin Endocrinol 2009;71:666-72.
18. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin d levels and the risk of mortality in the general population. Arch Intern Med 2008; 168:1629-37.
19. Jia X, Aucott LS, McNeill G. Nutritional status and subsequent all-cause mortality in men and women aged 75 years or over living in the community. Br J Nutr 2007;98:593-9.
20. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014;14:342-57.